Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors

Last updated: March 26, 2025
Sponsor: Jules Bordet Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

FAPI PET/CT

Clinical Study ID

NCT06107608
IJB-MN-LIFE1
  • Ages > 18
  • All Genders

Study Summary

Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent/metastatic disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age above 18 years.

  • Pathologically- proven non-small-cell lung cancer (NSCLC).

  • Proposed for treatment with anti-PD-(L)1 alone or in combination with chemotherapyand/or anti-CTLA4 in the advanced setting.

  • ECOG Performance status ≤2.

  • Patient's written informed consent obtained prior to any study procedure.

Exclusion

Exclusion Criteria:

  • Surgery and/or radiotherapy to thoracic region within the last 8 weeks oranti-cancer systemic therapy within the last 2 weeks.

  • Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and c-rosoncogene (ROS1) mutations.

  • Pregnant and lactating women

  • Previous or concurrent malignancy diagnosed within the last 2 years exceptadequately treated in situ carcinoma of the cervix uteri, localised (T1N0) low grade (Gleason score 6) prostate cancer undergoing active surveillance and basal orsquamous cell skin cancer.

  • Subjects with another significant medical condition which, in the investigator'sopinion, may interfere with the completion of the study.

Study Design

Total Participants: 58
Treatment Group(s): 1
Primary Treatment: FAPI PET/CT
Phase:
Study Start date:
June 13, 2023
Estimated Completion Date:
December 01, 2027

Study Description

Fibroblast activation protein (FAP), a type II membrane glycoprotein, is selectively expressed by cancer-associated fibroblasts (CAFs) in more than 90% of epithelial carcinomas. FAP also regulates antitumor immune response. For these reasons, FAP is an attractive target and molecular imaging biomarker to assess CAFs and the tumour's landscape before and during immunotherapy. The PET radiotracer 68Ga-FAPI (Fibroblast activation protein inhibitor) allows the visualisation and quantification of CAFs.This study will use a non-invasive technique to assess CAFs before and during immunotherapy and to evaluate diverse predictive biomarkers in a prospective setting studying simultaneously CAFs (using 68Ga-FAPI) and cfDNA.

Connect with a study center

  • Institut Jules Bordet

    Brussels, 1070
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.